Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 303 Stomach Neoplasms 34 Neoplasm Metastasis 24 Neoplasms 16 Colorectal Neoplasms 16 Breast Neoplasms, Male 16 HER2-positive Breast Cancer 11 Inflammatory Breast Neoplasms 10 Triple Negative Breast Neoplasms 9 Esophageal Neoplasms 9 Carcinoma, Non-Small-Cell Lung 8 Brain Neoplasms 8 Rectal Neoplasms 7 Adenocarcinoma 7 Colonic Neoplasms 6 Urinary Bladder Neoplasms 5 Pathologic Complete Response 5 Biliary Tract Neoplasms 5 Urologic Neoplasms 4 Salivary Gland Neoplasms 4 Prostatic Neoplasms 4 Lung Neoplasms 4 Gallbladder Neoplasms 4 Carcinoma, Ductal, Breast 4 Recurrence 3 Pancreatic Neoplasms 3 Neoplastic Cells, Circulating 3 Multiple Myeloma 3 Meningeal Neoplasms 3 HER2-positive Gastric Cancer 3

Interventions

relatlimab 2 linrodostat 2 Nivolumab 2 Ipilimumab 2 Vorinostat 1 Trastuzumab 1 IFL protocol 1 Gemcitabine 1 Dasatinib 1 Cetuximab 1 BMS-813160 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Cancer × Trastuzumab × Clear all

NCT05605509 2026-02-06

RP-6306 in Patients With Advanced Cancer

Canadian Cancer Trials Group

Phase 2 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡